InduPro, Inc.

About InduPro, Inc.

InduPro is focused on advancing science in proximity-based therapeutics by manipulating protein interactions on cell surfaces to treat diseases. Their vision is to improve human health through a two-fold strategy and proprietary platforms that facilitate new biology and develop life-changing medicines.

Products & Services

Proximity-Based Therapeutics:Innovative therapies that bring proteins on cell surfaces closer together to manipulate interactions and treat diseases.

Proprietary Platforms:Platforms designed to explore spatial relationships in biology and induce proximity for drug development.

Specialties

Proximity-Based Therapeutics Spatial Relationships in Biology Drug Therapy Innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 85000000 MR: - FA: $85 million FAN: 85000000	D: 2024-06-13 FD: 2024-06-13	5 investors

Series A Latest

2024-06-13

$85.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Prakash Raman

CEO

S

Scott Lesley

President & Chief Scientific Officer

P

Pamela Holland

SVP of Biology

N

Niyi Fadeyi

VP of Chemical Sciences

R

Rob Oslund

VP of Platform Technology

E

Ertan Eryilmaz

VP of Biologics

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

InduPro, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised